Download this poster now
Novel Gastro-Retentive Formulation for Methyldopa Using Hot Melt Extrusion (HME) Technology
Type 1 diabetes, also called Juvenile diabetes, is an auto-immune condition where the pancreas produces little or no insulin. The only known treatment involves insulin administration which manages the symptoms without treating the cause. Methyldopa has been shown to re-program T-cells, which protect the islet cells in the pancreas from destruction. Absorption is limited to 50% in oral doses in the upper gastrointestinal tract. Hence, a gastro-retentive dosage form is required to increase absorption efficiency of methyldopa.
Ruchit Trivedi, David Zama, Mark Previti, and J. Blair West
Poster on formulation of a novel gastro-retentive sustained release oral formulation for methyldopa to treat Type I diabetes, presented by Ruchit Trivedi, Ph. D., at AAPS 2016.